Royalty Report: Drugs, cardiac, Disease – Collection: 248329


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • cardiac
  • Disease
  • Therapeutic
  • Genome
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 248329

License Grant
The Canadian Licensor hereby grants to Licensee of Netherlands within the Field of Use, and Licensee accepts, the exclusive worldwide right, sublicense and privilege under the Licensor Licensed Rights to use the Licensor Licensed Technology and to use, manufacture, distribute and sell Licensed Products.  Licensee shall sponsor the research Project as defined in the Collaborative Research Agreement between Licensor and University and, for that purpose, Licensee and Licensor entered into Heads of Agreement effective August 1, 2000.
License Property
Project means the project description entitled “LPL Gene Therapy for LPL Deficiency”, which is attached to the Collaborative Research Agreement, including any amendments thereto which the Parties and University may mutually agree to, from time to time, of the Collaborative Research Agreement.

The scientific collaboration is in the area of LPL gene therapy in humans including all research and development required for establishing a successful clinical LPL gene therapy protocol.

Licensed Product(s) means a Product using or made by a process using the Licensor Licensed Rights.

Description of Technology
U.S. 5,658,729 – Lipolipase Mutation 291, Implication for Coronary Artery Disease
U.S.  SN 08/737,954 – Recombinant Viruses Preparation and use thereof in Gene Therapy

Field of Use
Field of Use means gene therapy being the treatment of a disease caused by the malfunction of a gene, by transduction of cells of the organism with the normal gene or genetically altered gene.

IPSCIO Record ID: 245877

License Grant
The Parties,  both of the Netherlands,  agree that, with effect from the Effective Date, all of the Original Agreements shall terminate.

Licensor transfers and assigns its right, title or interest in the Existing Patent Rights to Licensee.

License Property
Licensee is a leading medical centre in the Netherlands which, amongst other activities, conducts research into the therapy, prophylaxis and diagnosis of various diseases and other conditions.

AAV Vector is an adeno-associated virus vector composed of a transgene cassette with limited length,  approximately 4.5 kb, flanked by an ITR DNA sequence.

FG Products are LPL Products, IL-10 Products and Nash Products.

IL-10 Product is a gene therapy product for the treatment of diseases and conditions caused by the deficiency or mutation of the IL-10 gene.

LPL Product is a gene therapy product for the treatment of diseases and conditions caused by lipoprotein lipase deficiency or mutation.

Nash Product is a gene therapy product for the treatment of non-alcoholic steatotic hepatitis.

The existing patent rights are for LPL variant therapeutics, and, IL-10 gene transfer to peripheral mononuclear cells, and, New method of treatment for non alcoholic steatotic hepatitis (NASH).

Field of Use
The field of use is as a gene therapy product for the treatment of non-alcoholic steatotic hepatitis.

IPSCIO Record ID: 29073

License Grant
The Licensee entered into an agreement with the University which granted us an exclusive worldwide license, with the right to sublicense, to certain technology covering development, manufacture, use and sale of gene therapy products based on FGF-4 for the treatment of coronary artery disease, peripheral vascular disease and congestive heart failure. FGF-4 shall mean Fibroblast Growth Factor 4, the amino acid sequence.
Field of Use
Field shall mean gene therapy for coronary artery disease, congestive heart failure, and peripheral vascular disease.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.